New REAL clinical entities

Richard I. Fisher, Thomas P Miller, Thomas M. Grogan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

PURPOSE: In 1994, the International Lymphoma Study Group proposed a 'Revised European-American Lymphoma (REAL) Classification of Lymphoid Neoplasms.' This classification system was developed because (1) new lymphoid disease entities have been recognized that are not part of the National Cancer Institute Working Formulation (WF) and (2) there was a need to develop a common classification system that could be used internationally. The REAL classification itself had never been tested, however, to determine whether it was reproducible or defined distinct clinicopathologic entities. Therefore, in the past two years, two studies were conducted by the Southwest Oncology Group (SWOG) Lymphoma Committee and the Non-Hodgkin's Lymphoma (NHL) Classification Project to validate the REAL classification. PATIENTS AND METHODS: The SWOG Lymphoma Committee reviewed the pathology and clinical course of 376 previously untreated patients with stage III or IV disease within WF categories A, B, C, D, or E who received full-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) in SWOG studies 7204, 7426, and 7713. No patients in this database had localized mucosa- associated lymphoid tissue (MALT) lymphoma. The NHL Classification Project performed a retrospective study of 1,403 consecutive patients with previously untreated NHL seen between 1988 and 1990 at nine sites around the world. Five expert hematopathologists reached a consensus diagnosis on every case by using histologic, clinical, and immunophenotypic data, and 20% of all cases were randomly reviewed. RESULTS: The most common diagnosis was diffuse large B-cell lymphoma (31%), which combines the large-cell and immunoblastic WF categories (WF G/H). The next most common diagnosis was follicular lymphoma (22%; WF B, C, and D). Marginal zone B-cell (including MALT), peripheral T- cell, small B-lymphocytic, and mantle cell lymphoma each constituted between 5% and 10% of diagnoses. Primary mediastinal large B-cell, anaplastic large T/null cell, high-grade B-cell, Burkitt-like, and precursor T-lymphoblastic lymphoma made up the remaining 10 most frequent diagnoses. CONCLUSIONS: The analyses conducted by the SWOG Lymphoma Committee and the NHL Classification Project have demonstrated that the REAL classification does define 'real' clinical entities that can be diagnosed by expert hematopathologists. The understanding gained from study of 'real' entities should permit hematologists/oncologists to better predict the clinical course of their patients and also to develop improved therapy.

Original languageEnglish (US)
JournalCancer Journal from Scientific American
Volume4
Issue numberSUPPL. 2
StatePublished - 1998
Externally publishedYes

Fingerprint

Lymphoma
Non-Hodgkin's Lymphoma
B-Lymphocytes
Mantle-Cell Lymphoma
Null Lymphocytes
Marginal Zone B-Cell Lymphoma
Follicular Lymphoma
Clinical Pathology
B-Lymphoid Precursor Cells
National Cancer Institute (U.S.)
Lymphoma, Large B-Cell, Diffuse
Vincristine
B-Cell Lymphoma
Lymphoid Tissue
Prednisone
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doxorubicin
Cyclophosphamide
Mucous Membrane
Retrospective Studies

Keywords

  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Lymphomas
  • MALT lymphoma
  • Mantle cell lymphoma
  • Peripheral T- cell lymphoma
  • REAL classification
  • Working formulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fisher, R. I., Miller, T. P., & Grogan, T. M. (1998). New REAL clinical entities. Cancer Journal from Scientific American, 4(SUPPL. 2).

New REAL clinical entities. / Fisher, Richard I.; Miller, Thomas P; Grogan, Thomas M.

In: Cancer Journal from Scientific American, Vol. 4, No. SUPPL. 2, 1998.

Research output: Contribution to journalArticle

Fisher, RI, Miller, TP & Grogan, TM 1998, 'New REAL clinical entities', Cancer Journal from Scientific American, vol. 4, no. SUPPL. 2.
Fisher, Richard I. ; Miller, Thomas P ; Grogan, Thomas M. / New REAL clinical entities. In: Cancer Journal from Scientific American. 1998 ; Vol. 4, No. SUPPL. 2.
@article{a7fd4511292f497e8f345ed25324edd7,
title = "New REAL clinical entities",
abstract = "PURPOSE: In 1994, the International Lymphoma Study Group proposed a 'Revised European-American Lymphoma (REAL) Classification of Lymphoid Neoplasms.' This classification system was developed because (1) new lymphoid disease entities have been recognized that are not part of the National Cancer Institute Working Formulation (WF) and (2) there was a need to develop a common classification system that could be used internationally. The REAL classification itself had never been tested, however, to determine whether it was reproducible or defined distinct clinicopathologic entities. Therefore, in the past two years, two studies were conducted by the Southwest Oncology Group (SWOG) Lymphoma Committee and the Non-Hodgkin's Lymphoma (NHL) Classification Project to validate the REAL classification. PATIENTS AND METHODS: The SWOG Lymphoma Committee reviewed the pathology and clinical course of 376 previously untreated patients with stage III or IV disease within WF categories A, B, C, D, or E who received full-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) in SWOG studies 7204, 7426, and 7713. No patients in this database had localized mucosa- associated lymphoid tissue (MALT) lymphoma. The NHL Classification Project performed a retrospective study of 1,403 consecutive patients with previously untreated NHL seen between 1988 and 1990 at nine sites around the world. Five expert hematopathologists reached a consensus diagnosis on every case by using histologic, clinical, and immunophenotypic data, and 20{\%} of all cases were randomly reviewed. RESULTS: The most common diagnosis was diffuse large B-cell lymphoma (31{\%}), which combines the large-cell and immunoblastic WF categories (WF G/H). The next most common diagnosis was follicular lymphoma (22{\%}; WF B, C, and D). Marginal zone B-cell (including MALT), peripheral T- cell, small B-lymphocytic, and mantle cell lymphoma each constituted between 5{\%} and 10{\%} of diagnoses. Primary mediastinal large B-cell, anaplastic large T/null cell, high-grade B-cell, Burkitt-like, and precursor T-lymphoblastic lymphoma made up the remaining 10 most frequent diagnoses. CONCLUSIONS: The analyses conducted by the SWOG Lymphoma Committee and the NHL Classification Project have demonstrated that the REAL classification does define 'real' clinical entities that can be diagnosed by expert hematopathologists. The understanding gained from study of 'real' entities should permit hematologists/oncologists to better predict the clinical course of their patients and also to develop improved therapy.",
keywords = "Diffuse large B-cell lymphoma, Follicular lymphoma, Lymphomas, MALT lymphoma, Mantle cell lymphoma, Peripheral T- cell lymphoma, REAL classification, Working formulation",
author = "Fisher, {Richard I.} and Miller, {Thomas P} and Grogan, {Thomas M.}",
year = "1998",
language = "English (US)",
volume = "4",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - New REAL clinical entities

AU - Fisher, Richard I.

AU - Miller, Thomas P

AU - Grogan, Thomas M.

PY - 1998

Y1 - 1998

N2 - PURPOSE: In 1994, the International Lymphoma Study Group proposed a 'Revised European-American Lymphoma (REAL) Classification of Lymphoid Neoplasms.' This classification system was developed because (1) new lymphoid disease entities have been recognized that are not part of the National Cancer Institute Working Formulation (WF) and (2) there was a need to develop a common classification system that could be used internationally. The REAL classification itself had never been tested, however, to determine whether it was reproducible or defined distinct clinicopathologic entities. Therefore, in the past two years, two studies were conducted by the Southwest Oncology Group (SWOG) Lymphoma Committee and the Non-Hodgkin's Lymphoma (NHL) Classification Project to validate the REAL classification. PATIENTS AND METHODS: The SWOG Lymphoma Committee reviewed the pathology and clinical course of 376 previously untreated patients with stage III or IV disease within WF categories A, B, C, D, or E who received full-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) in SWOG studies 7204, 7426, and 7713. No patients in this database had localized mucosa- associated lymphoid tissue (MALT) lymphoma. The NHL Classification Project performed a retrospective study of 1,403 consecutive patients with previously untreated NHL seen between 1988 and 1990 at nine sites around the world. Five expert hematopathologists reached a consensus diagnosis on every case by using histologic, clinical, and immunophenotypic data, and 20% of all cases were randomly reviewed. RESULTS: The most common diagnosis was diffuse large B-cell lymphoma (31%), which combines the large-cell and immunoblastic WF categories (WF G/H). The next most common diagnosis was follicular lymphoma (22%; WF B, C, and D). Marginal zone B-cell (including MALT), peripheral T- cell, small B-lymphocytic, and mantle cell lymphoma each constituted between 5% and 10% of diagnoses. Primary mediastinal large B-cell, anaplastic large T/null cell, high-grade B-cell, Burkitt-like, and precursor T-lymphoblastic lymphoma made up the remaining 10 most frequent diagnoses. CONCLUSIONS: The analyses conducted by the SWOG Lymphoma Committee and the NHL Classification Project have demonstrated that the REAL classification does define 'real' clinical entities that can be diagnosed by expert hematopathologists. The understanding gained from study of 'real' entities should permit hematologists/oncologists to better predict the clinical course of their patients and also to develop improved therapy.

AB - PURPOSE: In 1994, the International Lymphoma Study Group proposed a 'Revised European-American Lymphoma (REAL) Classification of Lymphoid Neoplasms.' This classification system was developed because (1) new lymphoid disease entities have been recognized that are not part of the National Cancer Institute Working Formulation (WF) and (2) there was a need to develop a common classification system that could be used internationally. The REAL classification itself had never been tested, however, to determine whether it was reproducible or defined distinct clinicopathologic entities. Therefore, in the past two years, two studies were conducted by the Southwest Oncology Group (SWOG) Lymphoma Committee and the Non-Hodgkin's Lymphoma (NHL) Classification Project to validate the REAL classification. PATIENTS AND METHODS: The SWOG Lymphoma Committee reviewed the pathology and clinical course of 376 previously untreated patients with stage III or IV disease within WF categories A, B, C, D, or E who received full-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) in SWOG studies 7204, 7426, and 7713. No patients in this database had localized mucosa- associated lymphoid tissue (MALT) lymphoma. The NHL Classification Project performed a retrospective study of 1,403 consecutive patients with previously untreated NHL seen between 1988 and 1990 at nine sites around the world. Five expert hematopathologists reached a consensus diagnosis on every case by using histologic, clinical, and immunophenotypic data, and 20% of all cases were randomly reviewed. RESULTS: The most common diagnosis was diffuse large B-cell lymphoma (31%), which combines the large-cell and immunoblastic WF categories (WF G/H). The next most common diagnosis was follicular lymphoma (22%; WF B, C, and D). Marginal zone B-cell (including MALT), peripheral T- cell, small B-lymphocytic, and mantle cell lymphoma each constituted between 5% and 10% of diagnoses. Primary mediastinal large B-cell, anaplastic large T/null cell, high-grade B-cell, Burkitt-like, and precursor T-lymphoblastic lymphoma made up the remaining 10 most frequent diagnoses. CONCLUSIONS: The analyses conducted by the SWOG Lymphoma Committee and the NHL Classification Project have demonstrated that the REAL classification does define 'real' clinical entities that can be diagnosed by expert hematopathologists. The understanding gained from study of 'real' entities should permit hematologists/oncologists to better predict the clinical course of their patients and also to develop improved therapy.

KW - Diffuse large B-cell lymphoma

KW - Follicular lymphoma

KW - Lymphomas

KW - MALT lymphoma

KW - Mantle cell lymphoma

KW - Peripheral T- cell lymphoma

KW - REAL classification

KW - Working formulation

UR - http://www.scopus.com/inward/record.url?scp=0031827118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031827118&partnerID=8YFLogxK

M3 - Article

C2 - 9672769

AN - SCOPUS:0031827118

VL - 4

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - SUPPL. 2

ER -